Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma

Clinical trial NCT07657312 · RECRUITING

Trial details

NCT number: NCT07657312
Sponsor: Naresh Bumma
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Cytokine Release Syndrome Recurrent Multiple Myeloma Refractory Multiple Myeloma

Start date: 2026-08-01
Primary completion: 2027-12-31
Enrollment: 35

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.